Jamjoom Pharma is a Saudi Arabia-based pharmaceutical company committed to delivering affordable medicines to those who need them. It offers over 130 brands across 36 Middle East and Africa (MENA) countries, centered on chronic-disease medicines for heart disease, high blood pressure, asthma, allergy and gastrointestinal conditions. With manufacturing sites in Saudi Arabia, Egypt and Algeria, local production widens access. In Saudi Arabia's generic market it holds roughly 45% share alongside Pfizer.
B
NARRATIVE VALUE
Certainty
●●● high
●●● high
ABCDEFG
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
As of: 2026-Q3Status: ActiveCeiling reason: No confirmed −
History2026-Q3BHistory grows each quarter
Jamjoom Pharma: Affordable chronic-disease medicines across 36 MENA countries. The letter is B; certainty is high. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)
Main narrative
One person’s story (N1)
+ A single story
People in MENA with chronic conditions like heart disease, high blood pressure or asthma who struggled to afford medicine. Jamjoom's affordable generics reach them through local production. The benefit appears as a collective: it offers 130+ brands across 36 MENA countries.
Source nature: Jamjoom Pharma / P1 First-party / independent (industry). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- With manufacturing in Saudi Arabia, Egypt and Algeria, it holds roughly 45% of Saudi Arabia's generic market.P2 Independent (market research)
− effects (confirmed)
- No confirmed −.
Watching (unconfirmed; not counted in the assessment)
- A listed, for-profit pharma (main business is selling generics across MENA)
- industry-wide generic pricing/quality debates
- access figures are partly self-reported.
Looking ahead (not included in the assessment)
- Quantifying MENA access; expanding local production; maintaining quality and regulatory compliance; extending beyond chronic disease.
A second look
The plus is affordable chronic-disease medicine access for people in MENA (People), backed by 130+ brands, 36 countries and local production. But it is a listed, for-profit pharma whose main business is selling generics across MENA, with industry-wide debates over generic pricing and quality. Weighing the genuine medicine-access plus, B/high.
Sources
+N1Jamjoom Pharma｜About us / 130+ brands in 36 countries｜2025｜🔗
+ effectSaudi generic pharma market｜2025｜🔗
How to read this assessment
A Independently verified +, with no confirmed −
B Leans +, with independent backing
C Mixed. A confirmed − sets the ceiling, or much is unverified
D A serious confirmed − sets the ceiling
E A serious − reaches the core of the organization
F Serious and systemic, with little redeeming +
G Only extreme cases
Out of scope An entity whose core purpose is illegal
On hold Independent evidence is scarce on both + and −
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the narrative an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top